Price
$4.84-40.83%Social Signal Score
Analyst Ratings
15 analystsRevenue
$234.30M+63.94%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Joseph C. Papa Jr.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 900
- Beta
- 2.34
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 0.83
Financials
Revenue
$234.30M+63.9%Net Income
$-180.20M-944.4%EBITDA
$-156.30M-415.0%Free Cash Flow
$54.00M+441.0%EPS (diluted)
$-3.49-875.6%Shares Outstanding (diluted)
51.60M+4.4%Operating Expenses
$53.80MCash & Debt
$139.70MReturn of Capital
$9.00MRevenue by Segment (annual)
$742.90MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $742.90M | $52.60M | $0.98 |
| 2024 | $1.04B | $-190.60M | $-3.60 |
| 2023 | $1.05B | $-760.50M | $-14.85 |
| 2022 | $1.12B | $-211.60M | $-4.22 |
| 2021 | $1.77B | $219.50M | $4.10 |
| 2020 | $1.58B | $305.80M | $5.79 |
| 2019 | $1.11B | $54.50M | $1.06 |
| 2018 | $782.40M | $62.70M | $1.25 |
| 2017 | $560.90M | $82.60M | $1.98 |
| 2016 | $488.80M | $51.80M | $1.29 |
| 2015 | $489.33M | $62.87M | $1.63 |
| 2014 | $404.47M | $36.74M | $0.98 |
| 2013 | $312.75M | $31.14M | $0.86 |
| 2012 | $281.89M | $23.52M | $0.65 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from EBS's reported EPS growth of 3.2% a year over 13 years.
- EPS in 5 years
- $1.15
- Implied price
- $14.96
- Return from $7.24
- 15.6% a year
To earn 15.0% a year on these assumptions you'd need to buy at $7.44 — today's price is already 2.7% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 9 | 11 | 13 | 15 | 17 |
|---|---|---|---|---|---|
| -6.8% | -3.0% | 1.0% | 4.4% | 7.5% | 10.2% |
| -1.8% | 2.2% | 6.4% | 10.0% | 13.2% | 16.1% |
| 3.2% | 7.4% | 11.8% | 15.6% | 19.0% | 22.0% |
| 8.2% | 12.6% | 17.2% | 21.2% | 24.7% | 27.9% |
| 13.2% | 17.8% | 22.7% | 26.8% | 30.5% | 33.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50+66.67%Social Signal Score
Mentions (8)
- Newsinvezz.com·18h ago·Neutral
Russian plague outbreak could boost these under-the-radar pharma stocks Global biosecurity alarms are flashing after an incident at an anti-plague research facility in Siberia sparked a severe public health response. Following the fatal lab exposure of a researcher in Irkutsk region to Yersinia pestis – the bacterium causing pneumonic plague – Russian officials placed several regional hospitals under quarantine and isolated nearly 200 contacts.
View source ↗ - Newsglobenewswire.com·33d ago·Negative
…epurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has completed the repurchase of $75 million aggregate principal amount of its 3.875% Senior Unsecured Notes due 2028 (the “Senior Unsecured Notes”), following authorization granted by its Board of Directors. In total, Emergent deployed approximately $68 million of cash for the repurchases, resulting in a…
View source ↗ - Newsglobenewswire.com·36d ago·Neutral
Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray WINNIPEG, Manitoba, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has been awarded a standing offer by the Government of Canada, through a competitive procurement process, to supply NARCAN® Nasal Spray. The standing offer is effective from October 1, 2026, through September 30, 2029, with an option to extend for an additional two years.
View source ↗ - Newsglobenewswire.com·36d ago·Negative
…erdose Awareness Day GAITHERSBURG, Md., Aug. 31, 2026 (GLOBE NEWSWIRE) -- In recognition of International Overdose Awareness Day (IOAD), Emergent BioSolutions (NYSE: EBS) is reaffirming its commitment to expanding awareness of opioid overdose risks and increasing preparedness to help save lives. According to the World Health Organization, opioids are associated with nearly 80 percent of drug-related deaths worldwide, highlighting the continued need for education, preparedness and access to life-…
View source ↗ - Newsbusinesswire.com·48d ago·Negative
Emergent BioSolutions Inc. (EBS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Emergent BioSolutions Inc. (“Emergent BioSolutions” or the “Company”) (NYSE: EBS) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN EMERGENT BIOSOLUTIONS INC. (EBS), CONTACT THE L…
View source ↗ - Newsbusinesswire.com·48d ago·Negative
Securities Fraud Investigation Into Emergent BioSolutions Inc. (EBS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Emergent BioSolutions Inc. (“Emergent BioSolutions” or the “Company”) (NYSE: EBS) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON EMERGENT BIOSOLUTIONS INC. (E…
View source ↗ - Newsbusinesswire.com·49d ago·Negative
EBS Investors Have Opportunity to Join Emergent BioSolutions Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $EBS--EBS Investors Have Opportunity to Join Emergent BioSolutions Inc. Fraud Investigation with SBS Law.
View source ↗ - Newsmarketbeat.com·59d ago·Negative
Emergent Biosolutions Q2 Earnings Call Highlights Emergent Biosolutions NYSE: EBS reported second-quarter 2026 revenue and adjusted EBITDA above its prior guidance and analyst consensus, driven by accelerated medical countermeasure deliveries to U.S. government customers. The company also lowered its full-year outlook as increased competition and pricing pressure in the naloxone market are expected to weigh on sales of NARCAN.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $-0.37 per share
Typical surprise +161.5% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$0.60 vs $-0.09beat
- Thu, Apr 30$0.21 vs $-0.25beat
- Thu, Feb 26$-0.43 vs $0.11miss
- Wed, Oct 29$1.06 vs $-0.12beat
- Wed, Aug 6$0.16 vs $-0.26beat
- Wed, May 7$0.71 vs $0.49beat
Estimates and results for EBS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by EBS officers and directors.
- Bought
- $350k
- Sold
- $1.6m
1 trade
18 trades
- Williams Paul Anthonysold
- Williams Paul Anthonysold
- Dayal Sujata Tyagisold
- Dayal Sujata Tyagisold
- Degolyer Donald Wsold
- Degolyer Donald Wsold
- Zoon Kathryn Csold
- Zoon Kathryn Csold
81 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Stephen Cohenhouse · TN09 · disclosed Jan 10, 2025 (30d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Dec 13, 2021 (38d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Nov 15, 2021 (28d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Oct 13, 2021 (28d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Mar 10, 2021 (15d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Dec 15, 2020 (21d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Aug 19, 2020 (20d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jul 17, 2020 (17d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jul 17, 2020 (28d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jul 9, 2020 (24d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jul 9, 2020 (13d later)Buy$1,001 - $15,000
- Stephen Cohenhouse · TN09 · disclosed Apr 22, 2020 (27d later)Sell$1,001 - $15,000
- Stephen Cohenhouse · TN09 · disclosed Sep 12, 2019 (14d later)Sell$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.